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Abstract
Background:  Hereditary non-polyposis colon cancer (HNPCC) is an autosomal dominant syndrome
predisposing to the early development of various cancers including those of colon, rectum, endometrium,
ovarium, small bowel, stomach and urinary tract. HNPCC is caused by germline mutations in the DNA mismatch
repair genes, mostly hMSH2 or hMLH1.
In this study, we report the analysis for genetic counseling of three first-degree relatives (the mother and two
sisters) of a male who died of colorectal adenocarcinoma at the age of 23. The family fulfilled strict Amsterdam-
I criteria (AC-I) with the presence of extracolonic tumors in the extended pedigree. We overcame the difficulty
of having a proband post-mortem non-tumor tissue sample for MSI testing by studying the alleles carried by his
progenitors.
Methods: Tumor MSI testing is described as initial screening in both primary and metastasis tumor tissue blocks,
using the reference panel of 5 microsatellite markers standardized by the National Cancer Institute (NCI) for the
screening of HNPCC (BAT-25, BAT-26, D2S123, D5S346 and D17S250). Subsequent mutation analysis of the
hMLH1 and hMSH2 genes was performed.
Results: Three of five microsatellite markers (BAT-25, BAT-26 and D5S346) presented different alleles in the
proband's tumor as compared to those inherited from his parents. The tumor was classified as high frequency
microsatellite instability (MSI-H). We identified in the HNPCC family a novel germline missense (c.1864C>A)
mutation in exon 12 of hMSH2 gene, leading to a proline 622 to threonine (p.Pro622Thr) amino acid substitution.
Conclusion: This approach allowed us to establish the tumor MSI status using the NCI recommended panel in
the absence of proband's non-tumor tissue and before sequencing the obligate carrier. According to the Human
Gene Mutation Database (HGMD) and the International Society for Gastrointestinal Hereditary Tumors
(InSiGHT) Database this is the first report of this mutation.
Published: 20 January 2006
BMC Medical Genetics 2006, 7:5 doi:10.1186/1471-2350-7-5
Received: 25 April 2005
Accepted: 20 January 2006
This article is available from: http://www.biomedcentral.com/1471-2350/7/5
© 2006 Chialina et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Medical Genetics 2006, 7:5 http://www.biomedcentral.com/1471-2350/7/5
Page 2 of 5
(page number not for citation purposes)
Background
Hereditary non-polyposis colorectal cancer (HNPCC) is
an inherited syndrome predisposing to the early develop-
ment of cancers of colon, rectum, endometrium, ovarium,
small bowel, stomach and urinary tract [1,2].
Since there are no premonitory signs of susceptibility to
HNPCC, family history has been the primary method for
identifying patients at risk. Defined by the International
Collaborative group on HNPCC, the typical HNPCC fam-
ily fulfill the following criteria (referred to as the Amster-
dam-I criteria [3]): 1. Three or more relatives with
histologically verified colorectal cancer, one of whom is a
first-degree relative of the other two; 2. Colorectal cancer
affecting at least 2 successive generations; and 3. At least
one relative diagnosed with colorectal cancer under the
age of 50. The fulfillment of these criteria prompted fur-
ther genetics investigations. More recently it has been
revised to take into account the prevalence of extracolonic
cancer in certain HNPCC families [4].
This autosomal dominantly inherited disorder is caused
by germline mutations in genes coding proteins responsi-
ble for the repair of DNA replication errors, which are
referred to as DNA mismatch repair (MMR) genes [5].
DNA mismatch repair machinery plays a critical role in
genomic stability, including correction of mispaired bases
associated with DNA replication and recombination.
Germline mutations in one allele of any of these genes fol-
lowed by the somatic loss or inactivation of the wild-type
allele leads to a defective mismatch repair mechanism.
The current "gold standard" for assessing tumor DNA
MMR activity is molecular microsatellite instability (MSI)
testing. In most cases, it involves extracting DNA from
both tumor and normal tissue. The DNA is subjected to
polymerase chain reaction (PCR) amplification of five or
more different chromosomal loci that compare "microsat-
ellites", running the PCR products through a gel to sepa-
rate DNA fragments by size, comparing the tumor-normal
pairs, and scoring for differences between the two. Insta-
bility at two or more out of five markers defines a tumor
as MSI-H and prompts further analysis, as sequencing of
DNA MMR genes. A number of them have been associated
with HNPCC, including hMSH2, hMLH1, hPMS1, hPMS2,
hMSH3, and hMSH6. Most of the HNPCC families in
which mutations have been identified involved hMSH2
and hMLH1 genes [6].
A much less labor-intensive alternative method used to
prescreen high-risk individuals for further germline muta-
tion analysis is immunohistochemistry (IHC) testing for
MLH1 and MSH2 expression. IHC testing may identify
which gene to target for analysis.
We describe MSI testing in the absence of proband non-
tumor tissue using the Bethesda consensus panel (mono-
nucleotide repeats BAT25 and BAT26, and dinucleotide
repeats D2S123, D5S346, and D17S250) and we report a
novel hMSH2 germline mutation found in the family.
Methods
Patients
Three first-degree relatives (mother and two sisters) of a
male who died of poorly differentiated colorectal adeno-
carcinoma at age 23 contacted us for genetic counseling. A
detailed family and medical history was obtained through
interview with the proband relatives and their consent for
release of medical records and use of the pathological tis-
sue blocks still available.
The early onset of the colon cancer in the proband and the
study of the family's pedigree (fig. 1), that fulfill the strict
Amsterdam-1 criteria, prompted genetic analysis with sus-
picion of HNPCC. They were informed about the risks,
benefits and limitations of the study protocol.
Pedigree showing HNPCC family Figure 1
Pedigree showing HNPCC family. An arrow indicates 
the male index patient (III:3) diagnosed with colorectal aden-
ocarcinoma at the age of 23 years. Family members suffering 
from a malignancy are indicated by a shaded circle or square. 
The age, type of malignancy, as well as the generation (roman 
figures), are described below the indicated patient. The fam-
ily fulfill the Amsterdam-I criteria with presence of extraco-
lonic tumors in the extended pedigree, having more than 
three carcinomas of colon (C) or ovary (O) in the affected 
members. The syndrome is present in all three generations 
(I-III) and three family members are younger than 50 years 
(III:3, II:1 and I:3). At the moment of the study the proband's 
mother (II-5) was an unaffected carrier, but two years later 
she developed an endometrial (E) adenocarcinoma.BMC Medical Genetics 2006, 7:5 http://www.biomedcentral.com/1471-2350/7/5
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Study protocol
As screening method for HNPCC we searched for MSI in
the proband's primary tumor and metastasis tissue blocks.
The absence of proband's non-tumor DNA for MSI testing
was overcome studying the alleles carried by his progeni-
tors. Once the MSI was established, a second blood sam-
ple was obtained from the proband's mother (obligate
carrier but at the moment of the study still unaffected) to
full mutation analysis of the hMSH2 and hMLH1 genes by
direct sequencing. After identifying the family mutation,
we searched it in both proband's sisters.
DNA preparation for genetic testing
Peripheral blood was collected from the three consulting
family members and the proband's father. Genomic DNA
isolation from their lymphocytes was performed using a
standard phenol-chloroform extraction. DNA from the
proband was obtained from the formalin-fixed, paraffin
embedded tissue blocks and isolated by microdissection
of tumor, deparaffinization, proteinase K treatment, and
ethanol precipitation [7].
Determination of MSI
The reference panel of 5 microsatellite markers standard-
ized by the National Cancer Institute for the screening of
HNPCC (BAT-25, BAT-26, D2S123, D5S346 and
D17S250) were PCR amplified using the corresponding
specific primers for each one [8]. All the PCR products
were electrophoresed through a denaturing 6% polyacry-
lamide gels and visualized by silver staining (fig. 2).
DNA sequencing of hMSH2 and hMLH1 genes
A second blood sample was obtained from the proband's
mother and forwarded to the Department of Clinical Can-
cer Genetics (City of Hope Cancer Center, Duarte, Califor-
nia, USA) to full mutation analysis of the hMSH2 and
hMLH1  genes. The sample was amplified followed by
direct sequencing to screen the coding regions of both the
hMSH2 and the hMLH1 genes for germline mutation in
the DNA.
After establishing the familial mutation in the proband's
mother, located in the exon 12 of hMSH2 gene, it was
searched in the proband's sisters by direct sequencing
using a manual Sequenase PCR products kit (Amersham
Biosciences).
Results and discussion
Our work shows that the absence of proband's non-tumor
DNA for MSI testing can be overcome by studying the alle-
les carried by his progenitors avoiding the need for initial
sequencing of the obligate carrier.
Although BAT-26 has been reported to be sufficient for
MSI-H detection even without normal tissue matching
[9], careful interpretation is needed if MSI-H detection is
based solely on this marker, since polymorphism at the
BAT-26 locus has been detected [10].
A more sensitive approach has been reported using a
quasimonomorphic mononucleotide markers panel (that
includes BAT-25 and BAT-26) without the need to match
normal DNA[11].
In the present case, we overcame the difficulty of having a
proband post-mortem non-tumor tissue sample for MSI
testing by studying the alleles carried by his progenitors.
Microsatellites are inherited according to Mendelian rules
like any other genetic markers. Each progenitor pass one
of its two alleles to its offspring and by definition, the alle-
les present in the proband's tumor tissue but absent in his
progenitors are the result of somatic mutation.
Microsatellite instability Figure 2
Microsatellite instability. Three of five microsatellite 
markers (BAT-25, BAT-26 and D5S346) presented different 
alleles (*) in the proband's primary tumor (T') and its metas-
tasis (T") of those inherited from his biological mother (BM) 
and father (BF).BMC Medical Genetics 2006, 7:5 http://www.biomedcentral.com/1471-2350/7/5
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Three out of five microsatellite markers (BAT-25, BAT-26
and D5S346) presented alleles in the proband's primary
tumor (T') and its metastasis (T") different from those
inherited from his parents. This observation suggested a
dysfunction of the mismatch repair system and the tumor
was classified as high frequency MSI (MSI-H) according to
the NCI workshop [12]. Direct sequencing of the hMSH2
and hMLH1 genes was indicated, detecting a novel germ-
line mutation, a c.1864C>A transversion in exon 12 of
hMSH2 gene at the heterozygous state (fig. 3) leading to a
proline 622 to threonine (p.Pro622Thr) amino acid sub-
stitution. This is the second report involving the 622
codon in HNPCC [13].
Evolutionary conservation, examined by alignment of
sequences of homologous proteins for several species (fig.
4), suggests a functional relevance for the amino acid
involved. This is also supported by the mutator pheno-
type described for Pro640Leu mutant yeast [14], homolo-
gous to Pro622Leu hMSH2 substitution in humans (fig.
4).
Mutation screening was done in both sisters to assign their
risk to develop HNPCC and other related cancers. We
found the mutation in one of them and opportune recom-
mendations for surveillance and prophylaxis were given.
Two years after that, the proband's mother, unaffected
during this study, developed an endometrial adenocarci-
noma.
Conclusion
We overcame the absence of proband's non-tumor DNA
for MSI testing by studying the alleles carried by his pro-
genitors, the natural approach for the research team due
its paternity testing background.
This strategy allowed us to perform the screening for
HNPCC using the recommended NCI microsatellite panel
before sequencing the obligate carrier.
We consider highly probable the disease-causing nature of
the germline mutation in the hMSH2 gene found in the
family. To establish it undoubtedly, both immunohisto-
chemical data of the investigated tumor and screening of
at least 100 chromosomes in healthy controls should be
performed. This is the second report of an HNPCC related
mutation in Argentina, involving the hMSH2 gene [15].
According to the Human Gene Mutation Database
(HGMD) [16] and the International Society for Gastroin-
DNA sequence analysis of hMSH2 exon 12 Figure 3
DNA sequence analysis of hMSH2 exon 12. Genomic 
DNA was isolated from leucocytes and PCR amplified with 
the help of hMSH2 exon 12 flanking primers. In the image the 
result of the sequencing using the PCR forward primer. Panel 
A: proband's mother (obligate carrier), positive for the muta-
tion. Panel B: negative control for the mutation.
Protein sequence alignment for hMSH2 and homologues Figure 4
Protein sequence alignment for hMSH2 and homologues. Human, Mouse, Rat, Chicken and Saccharomyces cerevisiae 
(the site of mutation is highlighted) protein sequence alignment. Evolutionary conservation may indicate the functional rele-
vance of the aminoacid involved for the structure or functioning of the protein. *UniProtKB/Swiss-Prot http://ca.expasy.org/Publish with BioMed Central    and   every 
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testinal Hereditary Tumors (InSiGHT) [17] Database we
are the first to report the mutation.
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